Imatinib (STI571)

Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Imatinib (STI571) Chemical Structure

Imatinib (STI571) Chemical Structure
Molecular Weight: 493.6

Validation & Quality Control

Product Use Citation(33)

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

PDGFR Inhibitors with Unique Features

Product Information

  • Compare PDGFR Inhibitors
    Compare PDGFR Products
  • Research Area

Product Description

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
IC50 100 nM 100 nM 600 nM
In vitro In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LAMA-84MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnT2TWM2OD1yLkC3N|A1KM7:TR?=NWTyTIw5W0GQR1XS
EM-2NULZeZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDRcVFNUUN3ME2wMlA5QDhizszNNV3NXpQyW0GQR1XS
MEG-01NXOzW3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTBwMEi5NlEh|ryPMlXDV2FPT0WU
BV-173MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkf5TWM2OD1yLkG4O|Qh|ryPM{HjbXNCVkeHUh?=
K-562MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvhXlhKSzVyPUCuNlI1OzJizszNM1LlSnNCVkeHUh?=
CGTH-W-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTBwM{izO|Qh|ryPM3PnW3NCVkeHUh?=
ST486NULCeGZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTBwNki1OEDPxE1?M4XZXHNCVkeHUh?=
NCI-H1436MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vncmlEPTB;MD65O|gxOSEQvF2=M{TTdnNCVkeHUh?=
NOS-1MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fDRmlEPTB;MT62OVM5OyEQvF2=MXHTRW5ITVJ?
A498NV7LWoFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTjcJBKSzVyPUKuOVczOjNizszNNXLtN4RFW0GQR1XS
BE-13Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX6yRplIUUN3ME2yMlYzOTB4IN88US=>M4Dwb3NCVkeHUh?=
SUP-T1NVTGZZh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTNwOEK5NFch|ryPMmjJV2FPT0WU
NCI-H1770MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTVwNUeyOlIh|ryPM3iwTHNCVkeHUh?=
IMR-5MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvSbXVKSzVyPU[uNlIyPDdizszNNWCxZ2hiW0GQR1XS
LB2241-RCCMm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRThwMEezPFQh|ryPNIDMc|JUSU6JRWK=
TGBC24TKBNXj5SFRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjTO|dKSzVyPUiuN|QxPTJizszNNGe3VIxUSU6JRWK=
SCC-15NFTue45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTFyLke3PFgh|ryPM2LE[nNCVkeHUh?=
BB49-HNCNVz5VYt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{j1T2lEPTB;MUSuN|M{PSEQvF2=MX;TRW5ITVJ?
ES7NVXiS2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHaNmdKSzVyPUG0Mlc{PzlizszNNWexc4RbW0GQR1XS
LB2518-MELMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf0WnNKSzVyPUG2MlYxQTRizszNNHOwbm5USU6JRWK=
NCI-H510ANX\MTlRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrJXm5{UUN3ME2xO{4zPDR{IN88US=>NEfFVGZUSU6JRWK=
TE-441-TMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvVR45kUUN3ME2xO{4zQDh4IN88US=>MYfTRW5ITVJ?
HHNI\tUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXsWXdUUUN3ME2xO{4{QTl7IN88US=>M{\2RnNCVkeHUh?=
LC4-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTF6LkC2OVIh|ryPNG\YSJBUSU6JRWK=
KARPAS-45M{HEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPrTpVtUUN3ME2xPE4yQDR6IN88US=>MUnTRW5ITVJ?
LB1047-RCCM2LQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmniTWM2OD1zOD60OFUzKM7:TR?=MVLTRW5ITVJ?
NKM-1NUH3U4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrGU3J3UUN3ME2xPU4{PTV{IN88US=>NEDWcppUSU6JRWK=
SCLC-21HM3;Z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXFeodKSzVyPUKwMlEzPDZizszNNXHCcFJEW0GQR1XS
RS4-11MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zMWGlEPTB;MkCuN|MxQCEQvF2=NIWyN41USU6JRWK=
ALL-POMmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;lTWM2OD1{MD64NVQ6KM7:TR?=MV7TRW5ITVJ?
GDM-1NWPYVm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJ{LkW5OFUh|ryPMULTRW5ITVJ?
DMS-79M13QTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XjemlEPTB;MkSuOFk{PCEQvF2=NVqyOJVYW0GQR1XS
MPP-89M4\MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjmRYFKSzVyPUK1MlY5PzRizszNM1TReXNCVkeHUh?=
NB10NF7lZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTmT3FKSzVyPUK2MlQ3QTlizszNNX3idWNDW0GQR1XS
LS-513M4OwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXIdXhJUUN3ME2yOk45QDR5IN88US=>NYD3eWlGW0GQR1XS
L-540NWLre4F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTJ4LkmxOFMh|ryPMWDTRW5ITVJ?
ES1MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\lTFJ{UUN3ME2yO{42OjFizszNM1HtTHNCVkeHUh?=
NTERA-S-cl-D1Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTNyLkWwPVMh|ryPNHzhb4ZUSU6JRWK=
EW-1NUGyZXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDmTWM2OD1|Mj65OFU1KM7:TR?=MV7TRW5ITVJ?
Calu-6Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XafmlEPTB;M{OuNVg2PSEQvF2=M4rERnNCVkeHUh?=
CTV-1NGG0T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfZXXBKSzVyPUOzMlk4QDlizszNMl33V2FPT0WU
YTNXfZR5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXX2V5d3UUN3ME2zPE42OjB7IN88US=>Ml3LV2FPT0WU
TE-6NUm3bpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3v3WmlEPTB;NEGuNlc6QCEQvF2=Mmr6V2FPT0WU
HT-144M2jMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXruSJFjUUN3ME20NU42PDh4IN88US=>NUXyWJBTW0GQR1XS
EW-13MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTR{LkK3PVEh|ryPNX:4eolvW0GQR1XS
KALS-1NW[0dlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjtOm1KSzVyPUSzMlE{OjlizszNNFXhd5dUSU6JRWK=
MOLT-16NELBOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzw[W9DUUN3ME20OU4xPzV{IN88US=>Mn3HV2FPT0WU
D-336MGMn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NET2O2FKSzVyPUS1Mlk2QTlizszNNHfHNYhUSU6JRWK=
TE-11M2TYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW[0NnVbUUN3ME20Ok43PTNizszNMWHTRW5ITVJ?
EB2MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTSXnd2UUN3ME20Ok43QTlizszNM1\jUHNCVkeHUh?=
SK-N-DZNGj0Z|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHKyVFJKSzVyPUS4MlA6PjFizszNNFvpbXZUSU6JRWK=
SW684M3znS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTR6LkK2PVUh|ryPNH3rUJJUSU6JRWK=
EW-18MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrMXWRKSzVyPUS4MlQ{QTVizszNMnvBV2FPT0WU
RL95-2MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnVN5BKSzVyPUWwMlA4OSEQvF2=MYTTRW5ITVJ?
CHP-126MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnznTWM2OD13MD64PVA2KM7:TR?=NHz5fJNUSU6JRWK=
NCI-H1395M3PLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjWTWM2OD13MT63PFM2KM7:TR?=M3j2bHNCVkeHUh?=
TE-15NUPscHRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHS5OHZKSzVyPUWyMlI2PTZizszNNWjIOokyW0GQR1XS
ES4MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVn4WVd4UUN3ME21Nk46Pzd3IN88US=>M2nx[3NCVkeHUh?=
TE-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3ThPWlEPTB;NUOuPVQ2PSEQvF2=MXPTRW5ITVJ?
SIMANXXmVHFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DOcWlEPTB;NUeuN|MyOSEQvF2=M3vmfnNCVkeHUh?=
LB647-SCLCNFX0dXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1L4W2lEPTB;NkSuNVE5QCEQvF2=MnfhV2FPT0WU
KY821M1vXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnoTJFtUUN3ME22OE4zPTV{IN88US=>MXvTRW5ITVJ?
LC-2-adNF;BZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEGzNHFKSzVyPU[1Mlc3ODFizszNMYLTRW5ITVJ?
KP-N-RT-BM-1NEjqcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nWWGlEPTB;Nk[uOlM3PiEQvF2=NGrid|ZUSU6JRWK=
SW872MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XqXGlEPTB;NkeuOFM5OiEQvF2=Mkm0V2FPT0WU
ES5MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPSR2RqUUN3ME22O{43QTZ6IN88US=>MmrjV2FPT0WU
SK-NEP-1M1j2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nRbGlEPTB;NkiuN|gxOyEQvF2=NFrKOopUSU6JRWK=
RPMI-6666M{f2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX2WoR3UUN3ME23NU4xOzJizszNMYDTRW5ITVJ?
UACC-812MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2T3VWlEPTB;N{GuNVYxQSEQvF2=MoLvV2FPT0WU
COLO-829MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkG1TWM2OD15Mj62PVg4KM7:TR?=NXXyZpFZW0GQR1XS
KP-N-YSNGLkTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXr1SZU3UUN3ME23Nk44OTN7IN88US=>NVLLTW4zW0GQR1XS
GI-1NVrSSolIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1[xOWlEPTB;N{OuNlg3QCEQvF2=M1fnb3NCVkeHUh?=
ETK-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDrd5pGUUN3ME23N{41QTN{IN88US=>NYHjOHJMW0GQR1XS
LXF-289NXHp[21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTd|LkeyPUDPxE1?M3jjUHNCVkeHUh?=
CAS-1NIfwWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTpTWM2OD15Mz64PFU4KM7:TR?=NIn4RZlUSU6JRWK=
EW-22NFLUPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHyTWM2OD15ND63NVE2KM7:TR?=NFLWOlJUSU6JRWK=
NCI-H2196M4nkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVv0dHBvUUN3ME23OU43Ozd7IN88US=>MUPTRW5ITVJ?
EoL-1-cellM4XFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRThzLk[5OlMh|ryPMUfTRW5ITVJ?
D-247MGMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXzSJpKSzVyPUiyMlAzPDhizszNMXzTRW5ITVJ?
BeckerNELDVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrVPI1KSzVyPUiyMlM1QDFizszNMVLTRW5ITVJ?
IST-MEL1NVH3SnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLQTWM2OD16Mj6zOFgzKM7:TR?=MYXTRW5ITVJ?
MDA-MB-134-VIMmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHWwVJJKSzVyPUiyMlU6QTZizszNMWfTRW5ITVJ?
NCI-H1092NGrQ[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHGTXRKSzVyPUi0MlAyQTdizszNNWe0XI5SW0GQR1XS
KINGS-1MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3:2OWlEPTB;OE[uNVYyQCEQvF2=NEPVUXhUSU6JRWK=
HCC2218M1\pOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGGydnNKSzVyPUi2Mlc6OTNizszNMUXTRW5ITVJ?
GI-ME-NMoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7ib2xoUUN3ME24O{44Pjl7IN88US=>NF3Ee5BUSU6JRWK=
AM-38NFfj[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDrd2JoUUN3ME24PE4{QTV|IN88US=>M3z0UXNCVkeHUh?=
KNS-42NYTrZXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn35TWM2OD16OT6xNFE5KM7:TR?=Ml3jV2FPT0WU
C8166MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HNUmlEPTB;OEmuOlEzPSEQvF2=M1r0b3NCVkeHUh?=
Ramos-2G6-4C10M1;RbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jwNmlEPTB;OEmuPFcyQSEQvF2=M4PuV3NCVkeHUh?=
CTB-1Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnReJZKSzVyPUmwMlY{PTdizszNM3eycnNCVkeHUh?=
HCE-4MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TVe2lEPTB;OUGuNVM{PiEQvF2=MlPQV2FPT0WU
NCI-H526MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\DSYFKSzVyPUmyMlQyODNizszNMYnTRW5ITVJ?
ECC4NXvudpZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTl2LkK1OVUh|ryPM1LoR3NCVkeHUh?=
NCCITNUjlRZAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Th[GlEPTB;OUWuN|I6OiEQvF2=MkX4V2FPT0WU
MZ7-melMon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DTW2lEPTB;OUWuPVA1KM7:TR?=MWXTRW5ITVJ?
COLO-684NHrle5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnSU|ViUUN3ME25Ok4zOzh3IN88US=>M1;HcXNCVkeHUh?=
SU-DHL-1NYfIb3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1[3R2lEPTB;OU[uPVg1OiEQvF2=MnvVV2FPT0WU
SF126NGXCNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTXTWM2OD17Nz61NlE4KM7:TR?=MYTTRW5ITVJ?
NMC-G1MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{KxVWlEPTB;OUiuOFU2PCEQvF2=NF\hNIVUSU6JRWK=
NB14MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTl6LkmyNFgh|ryPNF3NOXRUSU6JRWK=
VA-ES-BJNYDiRmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTl7LkSwOVYh|ryPNVnReI5lW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

PDGF receptor kinase activity PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.

Cell Assay: [3]

Cell lines BON-1 cells and NCI-H727 cells
Concentrations ~100 μM
Incubation Time 48 hours
Method BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.

Animal Study: [5]

Animal Models SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
Formulation Imatinib is diluted in water.
Dosages 70 or 100 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Buchdunger E, et al. Proc Natl Acad Sci USA. 1995, 92(7), 2558–2562.

[2] Heinrich MC, et al. Blood. 2000, 96(3), 925-932.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02602314 Not yet recruiting Chronyc Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto February 2016 Phase 4
NCT02638428 Not yet recruiting Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML Samsung Medical Center|Ministry of health & welfare, Repu  ...more Samsung Medical Center|Ministry of health & welfare, Republic of Korea December 2015 Phase 2
NCT02611492 Not yet recruiting Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Assistance Publique - Hôpitaux de Paris December 2015 Phase 3
NCT02644525 Not yet recruiting Loaisis National Institute of Allergy and Infectious Diseases (NI  ...more National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) December 2015 Phase 2
NCT02614404 Recruiting Plasmodium Falciparum Malaria HuLow|Purdue University|University of Turin, Italy|Univer  ...more HuLow|Purdue University|University of Turin, Italy|Università degli Studi di Sassari|Hue University November 2015 Phase 1|Phase 2

view more

Chemical Information

Download Imatinib (STI571) SDF
Molecular Weight (MW) 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms CGP057148B, ST-1571
Solubility (25°C) * In vitro DMSO 3 mg/mL (6.07 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-​[(4-​methyl-​1-​piperazinyl)​methyl]​-​N-​[4-​methyl-​3-​[[4-​(3-​pyridinyl)​-​2-​pyrimidinyl]​amino]​phenyl]​-benzamide

Customer Product Validation (4)


Click to enlarge
Rating
Source FASEB J 2011 25, 3661-3673. Imatinib (STI571) purchased from Selleck
Method Apoptosis assay
Cell Lines Ba/F3-p210T315I cells
Concentrations 0-5 μM
Incubation Time 24 h
Results In a parallel study using imatinib/PDMP or nilotinib/PDMP combinations, to our surprise, similar significant synergy in Ba/F3-p210T315I cells was observed.

Click to enlarge
Rating
Source Leukemia Res 2012 36, 1311-1314. Imatinib (STI571) purchased from Selleck
Method Thymidine uptake Uptake assay
Cell Lines K562, MEG-01 cells
Concentrations 0.1-10 uM
Incubation Time 20 min
Results The effect of imatinib on nucleoside transport was first examined with thymidine. At a 10-M concentration, imatinib was able to inhibit the entry of radiolabeled thymidine in K562 cells by 76%. Imatinib was still efficient and blocked by 43% the entry of thymidine at 1 uM, but its effect on thymidine transport at 0.1 uM was not significant (Fig. 1a).

Click to enlarge
Rating
Source Dr. Thomas Kruwel of Fraunhofer. Imatinib (STI571) purchased from Selleck
Method Cell Viability assay
Cell Lines A2C12/BetaD5/GammaA3/GammaD12/A549/CaCo2/HepG2 cell lines
Concentrations 0.0001-1000 nM
Incubation Time 24/96 h
Results

Click to enlarge
Rating
Source Dr. Helen Rizos from the university of Sydney. Imatinib (STI571) purchased from Selleck
Method Western blot
Cell Lines MelMS melanoma cell line
Concentrations 50 nM
Incubation Time 24/72 h
Results

Product Use Citation (33)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PDGFR Products

  • AZD2932

    AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.

  • Sunitinib

    Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Sunitinib Malate

    Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

  • CP-673451

    CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM in cell-free assays, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.

  • PP121

    PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.

  • Crenolanib (CP-868596)

    Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.

  • Tyrphostin AG 1296

    Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.

  • Sennoside B

    Sennoside B, a kind of irritant laxative isolated from rhei rhizome, inhibits PDGF-stimulated cell proliferation.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

Recently Viewed Items

Tags: buy Imatinib (STI571) | Imatinib (STI571) ic50 | Imatinib (STI571) price | Imatinib (STI571) cost | Imatinib (STI571) solubility dmso | Imatinib (STI571) purchase | Imatinib (STI571) manufacturer | Imatinib (STI571) research buy | Imatinib (STI571) order | Imatinib (STI571) mouse | Imatinib (STI571) chemical structure | Imatinib (STI571) mw | Imatinib (STI571) molecular weight | Imatinib (STI571) datasheet | Imatinib (STI571) supplier | Imatinib (STI571) in vitro | Imatinib (STI571) cell line | Imatinib (STI571) concentration | Imatinib (STI571) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us